↓ Skip to main content

Rivastigmine for Alzheimer's disease

Overview of attention for article published in Cochrane database of systematic reviews, April 2009
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (60th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

policy
1 policy source

Citations

dimensions_citation
140 Dimensions

Readers on

mendeley
46 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Rivastigmine for Alzheimer's disease
Published in
Cochrane database of systematic reviews, April 2009
DOI 10.1002/14651858.cd001191.pub2
Pubmed ID
Authors

Jacqueline Birks, John Grimley Evans, Vasso Iakovidou, Magda Tsolaki, Birks, Jacqueline, Grimley Evans, John, Iakovidou, Vasso, Tsolaki, Magda

Abstract

Alzheimer's disease (AD) is the commonest cause of dementia affecting older people. One of the therapeutic strategies aimed at ameliorating the clinical manifestations of Alzheimer's disease is to enhance cholinergic neurotransmission in relevant parts of the brain by the use of cholinesterase inhibitors to delay the breakdown of acetylcholine released into synaptic clefts. Tacrine, the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity. Other cholinesterase inhibitors, including rivastigmine, with superior properties in terms of specificity of action and low risk of adverse effects, have now been introduced. Rivastigmine has received approval for use in 60 countries including all member states of the European Union and the USA.

Mendeley readers

The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 46 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 11 24%
Student > Doctoral Student 6 13%
Student > Bachelor 3 7%
Unspecified 2 4%
Student > Ph. D. Student 2 4%
Other 2 4%
Unknown 20 43%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 9 20%
Medicine and Dentistry 8 17%
Unspecified 3 7%
Economics, Econometrics and Finance 3 7%
Nursing and Health Professions 1 2%
Other 2 4%
Unknown 20 43%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 June 2012.
All research outputs
#3,453,652
of 12,100,779 outputs
Outputs from Cochrane database of systematic reviews
#4,299
of 7,978 outputs
Outputs of similar age
#37,538
of 129,240 outputs
Outputs of similar age from Cochrane database of systematic reviews
#46
of 77 outputs
Altmetric has tracked 12,100,779 research outputs across all sources so far. This one is in the 49th percentile – i.e., 49% of other outputs scored the same or lower than it.
So far Altmetric has tracked 7,978 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.6. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 129,240 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.
We're also able to compare this research output to 77 others from the same source and published within six weeks on either side of this one. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.